PCSK9 and acute coronary syndrome: In comparison, the NNT to prevent 1 MACE event was 22 over 5 years in the FRISC‐II (Framingham and Fast Revascularization During Instability in Coronary Artery Disease) trial,23 50 at 7 years in IMPROVE‐IT (The Improved Reduction of Outcomes: Vytorin Efficacy International Trial),24 67 at 2.2 years in FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk), 63 at 2.8 years in ODYSSEY OUTCOMES (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab).25, 26, 27